![Mark Enyedy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Net worth: 2 M $ as of 2026-08-30
Mark Joseph Enyedy is an Independent Director at BioMarin Pharmaceutical, Inc. since 2023.
Mr. Enyedy is an Independent Director at Charles River Laboratories International, Inc. starting in 2025.
Mr. Enyedy is an Independent Outside Director at Astellas Pharma, Inc. starting in 2025.
Mr. Enyedy was President, Chief Executive Officer & Director at ImmunoGen, Inc. from 2016 to 2024.
Mr. Enyedy was Chief Executive Officer & Director at Proteostasis Therapeutics, Inc. from 2011 to 2013.
Mr. Enyedy was Independent Director at Keryx Biopharmaceuticals, Inc. from 2017 to 2018.
Mr. Enyedy was Independent Director at Akebia Therapeutics, Inc. from 2018 to 2021.
Mr. Enyedy was Director at Biotechnology Innovation Organization.
Mr. Enyedy was Director at American Cancer Society, New England Division, Inc. Mr. Enyedy was Independent Director at Fate Therapeutics, Inc. from 2013 to 2018.
Mr. Enyedy was Independent Director at LogicBio Therapeutics, Inc. from 2020 to 2022.
Mr. Enyedy was Independent Non-Executive Director at Ergomed Group Ltd. from 2021 to 2023.
Mr. Enyedy was SVP, President-Transplant & Multiple Sclerosis at Genzyme Corp.
from 2011 to 2012.
Mr. Enyedy was Executive VP & Head-Corporate Development at Shire Plc from 2014 to 2016.
Mr. Enyedy was Associate at Palmer & Dodge LLP.
Mr. Enyedy completed undergraduate education at Northeastern University.
Mr. Enyedy completed graduate education at Harvard Law School.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-01 | 21,040 ( 0.01% ) | 1 M $ | 2026-08-30 | |
| 2026-05-07 | 2,384 ( 0% ) | 687 164 $ | 2026-08-30 |
| Companies | Position | Start |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Director/Board Member | 2023-12-26 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Director/Board Member | 2025-05-19 |
| ASTELLAS PHARMA INC. | Director/Board Member | 2025-06-18 |
| Companies | Position | End |
|---|---|---|
| IMMUNOGEN, INC. | Chief Executive Officer | 2023-12-31 |
| ERGOMED | Director/Board Member | 2023-11-12 |
| LOGICBIO THERAPEUTICS, INC. | Director/Board Member | 2022-11-15 |
| AKEBIA THERAPEUTICS, INC. | Director/Board Member | 2021-06-01 |
| KERYX BIOPHARMACEUTICALS | Director/Board Member | 2018-12-11 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 17 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Charles River Laboratories International, Inc.
 Charles River Laboratories International, Inc. Miscellaneous Commercial ServicesCommercial Services Provides laboratory testing and research services on a contract basis | Commercial Services |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Palmer & Dodge LLP
 Palmer & Dodge LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Astellas Pharma, Inc.
 Astellas Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceuticals and related medical products | Health Technology |
Akebia Therapeutics, Inc.
 Akebia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for kidney diseases | Health Technology |
Fate Therapeutics, Inc.
 Fate Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Develops disease-modifying therapeutics for orphan and neurodegenerative diseases | Health Technology |
American Cancer Society, New England Division, Inc. | |
Harvard Law School
 Harvard Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ergomed Plc
 Ergomed Plc BiotechnologyHealth Technology Engages in research and development of drugs for oncology & rare diseases | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines and therapies for bone metabolism, cardiology, neurology and rare diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
